Forget McGregor-Mayweather. The biotech world has been waiting for months to hear about Novartis' pricing decision for Kymriah, its just-approved CAR-T therapy for cancer. That interest turned into anxiety days earlier when Gilead announced its purchase of Kite, given that Kite is expected to be the next company to market its own CAR-T treatment and Gilead…
Leave a Comment
Related Post